바이칼린을 유효성분으로 포함하는 약물남용 치료제
    1.
    发明公开
    바이칼린을 유효성분으로 포함하는 약물남용 치료제 有权
    药物滥用治疗药物,包括作为主要成分的胆固醇

    公开(公告)号:KR1020080002367A

    公开(公告)日:2008-01-04

    申请号:KR1020060061169

    申请日:2006-06-30

    Abstract: A therapeutic agent comprising baicalin is provided to inhibit and treat drug abuse and addiction formed by administration of narcotic anodynes or narcotics, and improve safety and efficiency of drug abuse treatment, so that it is useful for inhibition of drug abuse and addiction symptoms including place dependence, crawling behavior and head-twitch. A therapeutic agent for drug abuse and addiction formed by administration of narcotic anodynes or narcotics comprises baicalin extracted from Scutellariae radix extract as an effective ingredient, wherein the narcotic anodynes or narcotics include serotonin causing head-twitch behavior or morphine causing place dependence; the Scutellariae radix extract is prepared by extracting Scutellariae radix with hot water; the therapeutic agent inhibits head-twitch caused by serotonin; and the daily dosage of the baicalin is 8-16 mg/kg.

    Abstract translation: 提供包含黄芩苷的治疗剂以抑制和治疗通过施用麻醉药物或麻醉药物形成的药物滥用和成瘾,并且提高药物滥用治疗的安全性和效率,从而可用于抑制药物滥用和成瘾症状,包括地方依赖 爬行行为和头痛。 通过施用麻醉药物或麻醉剂形成的药物滥用和成瘾的治疗剂包括从黄芩提取物中提取的黄芩苷作为有效成分,其中麻醉药物或麻醉剂包括引起头痉挛行为的5-羟色胺或导致地方依赖的吗啡吗啡。 通过用热水提取黄芩制备黄芩提取物; 治疗剂可抑制5-羟色胺引起的头颤; 黄芩苷的日剂量为8-16mg / kg。

    L-THP를 유효성분으로 포함하는 약물남용 치료제
    3.
    发明授权
    L-THP를 유효성분으로 포함하는 약물남용 치료제 有权
    含有L-THP作为活性成分的药物滥用治疗

    公开(公告)号:KR101054093B1

    公开(公告)日:2011-08-09

    申请号:KR1020080122989

    申请日:2008-12-05

    Abstract: 본 발명은 L-테트라하이드로팔마틴(L-tetrahydropalmatine, L-THP)을 유효성분으로 하고, 약제학적으로 허용되는 담체를 포함하는 약물남용 치료제에 관한 것이다. 본 발명의 L-THP를 유효성분으로 하는 약물남용 치료제는 마약성 진통제 또는 마약의 투여에 의하여 형성되는 약물 의존성을 유의적으로 억제할 수 있으므로, 약물남용의 치료에 널리 활용될 수 있을 것이다.
    약물남용, 약물의존성, L-테트라하이드로팔마틴(L-THP)

    Abstract translation: 本发明涉及包含L-四氢巴马汀(L-THP)作为活性成分和药学上可接受的载体的药物滥用治疗剂。 由于药物滥用治疗本发明作为活性成分,能够抑制由麻醉性镇痛药或麻醉药给药显著形成药物依赖的L-THP,它将被广泛用于药物滥用的治疗。

    마약중독 치료제
    4.
    发明公开
    마약중독 치료제 有权
    治疗药物用于治疗NARCOTICS

    公开(公告)号:KR1020070013640A

    公开(公告)日:2007-01-31

    申请号:KR1020050068095

    申请日:2005-07-26

    CPC classification number: A61K36/539 A61K2236/331 Y10S514/812

    Abstract: A therapeutic agent for narcotics addiction is provided to inhibit drug addiction of the narcotic anodynes, so that side effects of the narcotic anodynes are suppressed. The therapeutic agent for narcotics addiction comprises the Scutellariae radix extract and betaine as effective ingredients, and a pharmaceutically acceptable carrier, wherein the Scutellariae radix extract is prepared by extracting Scutellariae radix with hot water, and drying and pulverizing it; and the mixing ratio of Scutellariae radix extract and betaine is 4:6 to 7:3.

    Abstract translation: 提供麻醉药物成瘾的治疗剂以抑制麻醉药物成瘾,从而抑制麻醉药物的副作用。 毒瘾治疗剂包括黄芩提取物和甜菜碱作为有效成分,以及药学上可接受的载体,其中黄芩提取物通过用热水提取黄芩制备,并干燥并粉碎; 黄芩提取物和甜菜碱的混合比为4:6〜7:3。

    바이칼레인을 유효성분으로 포함하는 약물남용 치료제
    5.
    发明公开
    바이칼레인을 유효성분으로 포함하는 약물남용 치료제 有权
    药物滥用和药物滥用治疗药物包含作为主动成分的胆红素

    公开(公告)号:KR1020080002374A

    公开(公告)日:2008-01-04

    申请号:KR1020060061176

    申请日:2006-06-30

    Abstract: An agent comprising baicalein is provided to inhibit occurrence of symptoms including place dependence, crawling behavior and head-twitch, caused by drug abuse and addiction without side effects, so that the drug abuse and addiction is treated. An agent comprising baicalein obtained from the extract of Scutellariae radix, which is prepared by extracting with hot water, treats drug abuse and addiction formed by administration of narcotic anodynes or narcotics, especially inhibits crawling behavior and place dependence formed by administering apomorphine and cocaine, respectively, wherein the daily dosage of bicalein is 8-16 mg/kg.

    Abstract translation: 提供包含黄芩素的药剂,以抑制药物滥用和成瘾引起的地方依赖性,爬行行为和头痛等症状的发生,而没有副作用,从而治疗药物滥用和成瘾。 通过由热水提取制备的黄芩提取物的黄芩苷的药剂治疗药物滥用和通过施用麻醉药物或麻醉剂形成的成瘾药物,特别是抑制爬行行为和放置通过施用阿朴吗啡和可卡因形成的依赖性 其中白蛋白的日剂量为8-16mg / kg。

    L-THP를 유효성분으로 포함하는 약물남용 치료제
    7.
    发明公开
    L-THP를 유효성분으로 포함하는 약물남용 치료제 有权
    药物滥用治疗药物和包含L-THP作为活性成分的药物

    公开(公告)号:KR1020100064512A

    公开(公告)日:2010-06-15

    申请号:KR1020080122989

    申请日:2008-12-05

    CPC classification number: A61K31/4745

    Abstract: PURPOSE: A therapeutic agent for drug abuse containing L-tetrahydropalmatine(L-THP) is provided to suppress drug abuse cause by drug administration. CONSTITUTION: A therapeutic agent for drug abuse contains L-tetrahydropalmatine(L-THP) as an active ingredient and pharmaceutically acceptable carrier. The L-THP is isolated from Corydalis ochotensis TURCZ. The therapeutic agent effectively suppresses drug dependence by serotonins or morphines. The morphines include amorphine.

    Abstract translation: 目的:提供含有L-四氢化他汀(L-THP)的药物滥用治疗剂,以抑制药物滥用引起的药物滥用。 构成:药物滥用治疗剂含有作为活性成分的L-四氢化他汀(L-THP)和药学上可接受的载体。 L-THP分离自紫堇(Corydalis ochotensis TURCZ)。 治疗剂有效地抑制了血清素或吗啡的药物依赖性。 吗啡包括吗啡。

    사이코사포닌 A를 유효성분으로 포함하는 약물남용 치료제
    9.
    发明授权
    사이코사포닌 A를 유효성분으로 포함하는 약물남용 치료제 有权
    사이코사포닌A를유효성분으로포함하는약물남용치제제

    公开(公告)号:KR100749931B1

    公开(公告)日:2007-08-17

    申请号:KR1020060061182

    申请日:2006-06-30

    Abstract: A therapeutic agent for drug abuse and addiction comprising saikosaponin A as an active ingredient is provided to suppress drug dependency formed by administration of narcotic analgesics or narcotics and treat drug abuse and addiction safely. The therapeutic agent for drug abuse and addiction comprises saikosaponin A isolated from Bupleuri radix as an active ingredient and pharmaceutically acceptable carriers, wherein the saikosaponin A is isolated from the Bupleuri radix containing saikosaponin A, B, C and D, alpha-spinasterol, stigmasterol, bupleurmol and eugenol through hot water extraction and suppresses head twitch response in mouse induced by drug abuse and addiction.

    Abstract translation: 提供含有柴胡皂苷A作为活性成分的药物滥用和成瘾治疗剂,以抑制由麻醉止痛药或麻醉药的给药形成的药物依赖性,并安全地治疗药物滥用和成瘾。 用于药物滥用和成瘾的治疗剂包含从柴胡中分离的柴胡皂苷A作为活性成分和药学上可接受的载体,其中柴胡皂苷A是从含柴胡皂苷A,B,C和D的柴胡根中分离得到的,α-菠菜甾醇,豆甾醇, bupleurmol和丁香酚通过热水提取并且抑制药物滥用和成瘾引起的小鼠头部抽搐反应。

Patent Agency Ranking